Collaborations & Alliances

Q BioMed, Mannin Research Advance AKI Treatment

Data shows that the Ang-Tie2 signaling pathway is a promising therapeutic target to prevent AKI

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Q BioMed Inc., a commercial stage biotech company, and its technology research partner Mannin Research Inc., presented positive data on a potential new treatment for acute kidney injury (AKI).    There is a significant opportunity to advance a therapeutic solution to treat AK and address a patient population that contributes to 20% of all hospitalizations in the U.S.  Current treatments for AKI are mainly supportive and do not treat the underlying condition. Mannin’s chief scientific o...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters